- Home
- UTG vs VKTX Comparison
UTG vs VKTX Comparison
Compare UTG & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTG | VKTX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | UTG | VKTX |
|---|---|---|
| Price | $34.01 | $29.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $95.32 |
| AVG Volume (30 Days) | 356.0K | ★ 4.3M |
| Earning Date | 01-01-0001 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.10 | $23.82 |
| 52 Week High | $43.90 | $43.15 |
Technical Indicators
Market Signals| Indicator | UTG | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 54.30 |
| Support Level | $33.52 | $26.47 |
| Resistance Level | $35.50 | $34.00 |
| Average True Range (ATR) | 0.74 | 1.64 |
| MACD | -0.07 | 0.50 |
| Stochastic Oscillator | 53.98 | 93.17 |
Price Performance
Historical ComparisonAbout UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.